A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Launched by ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S · Apr 18, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at the long-term effectiveness and safety of a treatment called SKYTROFA (lonapegsomatropin) for people with growth hormone deficiency. Growth hormone deficiency is a condition where the body doesn't produce enough growth hormone, which is important for growth and development. The study will collect information from patients who are already receiving SKYTROFA as part of their regular care in the United States.

To participate in this study, patients must currently be using SKYTROFA and be able to provide written consent. This trial is open to patients aged between 1 and 18 years, and it is important to note that those involved in other clinical studies cannot join this one. Participants can expect to share their experiences with the treatment, which will help researchers understand how well it works and how safe it is over time. Overall, this study aims to gather valuable information that could benefit future patients with growth hormone deficiency.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who are on treatment with SKYTROFA (lonapegsomatropin)
• • Patients being clinically managed in USA
• • Patients with an appropriate written informed consent/assent as applicable for the age of the patient
• Exclusion Criteria:
• • Patients participating in any interventional clinical study